Pfizer raises 2019 forecast on surging cancer drug sales

Pfizer Inc posted third-quarter profit well above analysts' estimates on higher sales of cancer drug Ibrance and arthritis medicine Xeljanz, encouraging the largest U.S. drugmaker to lift its earnings forecast for the year.